Cancer Research Technology
Log in Register
Menu

Anti-cMyc, Recombinant [9E10]

Invented at University of California, San Francisco

Info

Catalogue Number 152580
Applications WB
Antigen/Gene or Protein Targets c Myc epitope tag
Reactivity Human
Relevance Recombinant monoclonal antibody raised against sequence of c-Myc, a proto-oncogene heavily implicated in a variety of (hematopoietic) cancers.

Background and Research Application
Anti c-Myc is raised against the proto-oncogene c-Myc, analogous to the avian v-Myc gene a very strong proto-oncogene often found to be upregulated in cancer. Aberrant and constitutive expression of c-Myc has been particularly implicated in the upregulation of genes involved in cellular proliferation and has been identified in cancers include carcinoma of cervix, colon, breast, lung and stomach, plus a translocation leading to Burkitt’s lymphoma. The gene product of c-Myc (p62) is upregulated in various hematopoietic tumours.
Recombinant 9E10 recognises recombinant proteins incorporating a c-Myc epitope tag and detects human c-Myc protein as well as a peptide in random coil configuration not as a helix. This antibody is a recombinant version of the anti c-Myc 9E10 monoclonal antibody.
c-Myc is believed to regulate expression of 15% of all genes, hence its strong implicated in cancer and represents a promising therapeutic target. c-Myc has been shown to be involved in apoptosis, cell cycle progression, proliferation and differentiation. c-Myc carries out its healthy and oncogenic functions within the nucleus. The c-Myc protein is a 62 kDa transcription factor encoded by c-Myc gene on human chromosome 8q24.
Anti c-Myc was created to precipitate p62 from human cells and recognise the c-Myc gene product, particularly in immunoblots to enable quantification of c-Myc in cells.
Host Mouse
Immunogen Synthetic peptide (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA - 32 aa) corresponding to 408-439 of Human c-Myc conjugated to KLH.
Subclass IgG1 kappa
Formulation PBS only
Concentration 1mg/ml
Research Area Cancer, Cell Cycle, Epigenetics & Nuclear Signalling, Stem Cell Biology
Immunogen UniProt ID P01106
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Epitope QKLISEEDL in its random, free peptide conformation.
Anti c-Myc can be used to facilitate research into function pathology of c-Myc expression in normal and neoplastic cells. Anti c-Myc antibody has be used in protein localisation, immunohistochemistry, ELISA and protein purification, though identification of c-Myc tagged proteins.
The epitope recognised by anti c-Myc, comprising the amino acid sequence `Glu‐Gln‐Lys‐Leu‐Ile‐Ser‐Glu‐Glu‐Asp‐Leu‐Asn', can be expressed in a different protein context and still confers recognition by the anti c-Myc 9E10 antibody.

Concentration
1mg/ml as standard

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Original hybridoma first published in: Evan et al. 1985. Mol Cell Biol. 5(12):3610-6. PMID: 3915782.

Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Europe PMC ID: 3915782


Add a reference

References: 2 entries

Original hybridoma first published in: Evan et al. 1985. Mol Cell Biol. 5(12):3610-6. PMID: 3915782.

Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor